Earnings ·
LivaNova PLC reported second-quarter 2026 revenue of $390.6 million, a 10.8% increase from the prior year period
LIVNLivaNova PLC
LivaNova PLC reported second-quarter 2026 revenue of $390.6 million, a 10.8% increase from the prior year period. The company raised its full-year 2026 adjusted diluted earnings per share guidance to $4.30–$4.40 and constant-currency revenue growth expectations to 8%–9%. A favorable Italian tax ruling resulted in an €81.8 million ($95.4 million) discrete tax benefit related to the SNIA environmental liability. LivaNova also entered a long-term supply agreement with Thermo Fisher Scientific for oxygenator components and announced new executive appointments, including Stefano Folli as President of Cardiopulmonary. The company operates in the medical technology industry, providing solutions for neurological and cardiac conditions.